ClinicalTrials.gg
WithdrawnNCT03408561Updated Sep 17, 2019

Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer

An interventional study of Internet-Based Intervention and Survey Administration in Breast Carcinoma, Colon Carcinoma and Kidney Carcinoma, sponsored by University of Southern California. Withdrawn at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by University of Southern California · Not applicable, Interventional, and Health services research

Why this study was withdrawn
No accrual
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Sex
All
01

Study summary

This pilot clinical trial studies how well social media listening works in improving clinical trial recruitment in patients with cancer. Social media listening and recruitment on Twitter may enhance enrollment for cancer-related clinical trials.

Read the detailed description

PRIMARY OBJECTIVES:

I. Examine the feasibility (acceptance among University of Southern California [USC] Norris study team members and Twitter users in Los Angeles [LA] county) of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials.

II. Gain preliminary data on the impact (i.e., numbers recruited versus projected accrual compared to historic recruitment) of targeted social media listening (SML) as a tool for enhancing recruitment to cancer trials among Twitter users in LA county.

III. Estimate the effect size of the number of people enrolled associated with the use of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials.

OUTLINE:

Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.

02

Conditions studied

  • Breast Carcinoma
  • Colon Carcinoma
  • Kidney Carcinoma
  • Lymphoma
  • Non-Small Cell Lung Carcinoma
  • Prostate Carcinoma
03

In context

Breast Neoplasms

12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

University of Southern California is the lead sponsor of 789 studies on the registry; 136 are open to participants now.

Of its 69 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • TRIAL INCLUSION:
  • Focus on one of the following disease categories: non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma
  • Be a phase 1 trial in expansion, phase 2, or 3
  • Be interventional trials
  • Recruit in English
  • Be Institutional Review Board (IRB)-approved and open to accrual at USC Norris
  • Recruit for at least 9 months at the point of enrollment
  • Set monthly accrual target >= 1/ and annual accrual target >= 12
  • PATIENT INCLUSION:
  • Will include all prospective trial participants in this study that come from Twitter in response of our SM recruitment interventions, provided they meet the specific trial's eligibility criteria

Exclusion criteria

Exclusion Criteria:

  • TRIAL EXCLUSION:
  • Phase 1 trials in dose escalation
  • PATIENT EXCLUSION:
  • Persons who do not meet the eligibility criteria of any of the trials open to accrual will be excluded from participation, and persons who may be eligible (e.g., disease/histology, stage, prior treatment) but do not meet additional trial-specific requirements such as insurance or allergy to drug)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Health Services Research (message via Twitter)

    Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.

    Other: Internet-Based Intervention · Other: Survey Administration

Interventions

  • OtherInternet-Based Intervention

    Receive message via Twitter

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. User acceptance and satisfaction with social media (SM) as a recruitment method

    A questionnaire will be used assess the acceptance of and satisfaction with SM recruitment method among University of Southern California (USC) Norris study team members and Twitter users in Los Angeles (LA) county.

    Time frame: Up to 14 months

  2. Accrual rate

    To be determined by comparing monthly actual versus (vs.) projected rate of recruitment for the trial disease groups (i.e., non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma) using generalized estimating equations, accounting for intra-disease random effects and trends across the 12 months (9 months exposure per trial). These results will then be put into context of the historic recruitment for these diseases at the center.

    Time frame: Up to 14 months

07

Study locations

1 site
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
08

References and documents

Publications

  • Reuter K, Angyan P, Le N, Buchanan TA. Using Patient-Generated Health Data From Twitter to Identify, Engage, and Recruit Cancer Survivors in Clinical Trials in Los Angeles County: Evaluation of a Feasibility Study. JMIR Form Res. 2021 Nov 26;5(11):e29958. doi: 10.2196/29958. PubMed 34842538 ↗
  • Reuter K, Angyan P, Le N, MacLennan A, Cole S, Bluthenthal RN, Lane CJ, El-Khoueiry AB, Buchanan TA. Monitoring Twitter Conversations for Targeted Recruitment in Cancer Trials in Los Angeles County: Protocol for a Mixed-Methods Pilot Study. JMIR Res Protoc. 2018 Sep 25;7(9):e177. doi: 10.2196/resprot.9762. PubMed 30274964 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03408561
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Nov 8, 2017
Primary completion
Dec 31, 2018 (estimated)
Completion
Dec 31, 2018 (estimated)
Last update
Sep 17, 2019

Study contacts

Thomas Buchanan, MD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion